These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 6217639)

  • 41. Characterization of the interaction of recombinant apolipoprotein(a) with modified fibrinogen surfaces and fibrin clots.
    Sangrar W; Koschinsky ML
    Biochem Cell Biol; 2000; 78(4):519-25. PubMed ID: 11012092
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A.
    Pfitzner SA; Dempfle CE; Matsuda M; Heene DL
    Thromb Haemost; 1997 Sep; 78(3):1069-78. PubMed ID: 9308756
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Fibrinolysis activities and factor XIII in the neonatal period. 1. Fibrinolysis activity and fibrin degradation products in the neonatal period].
    Yamada Z
    Nihon Shonika Gakkai Zasshi; 1971 Apr; 75(4):294-6. PubMed ID: 4252802
    [No Abstract]   [Full Text] [Related]  

  • 44. [Nonenzymatic fibrinolysis].
    Dzhurdzhev A; Atanasov K
    Vutr Boles; 1981; 20(3):18-22. PubMed ID: 6455858
    [No Abstract]   [Full Text] [Related]  

  • 45. Fibrinogen break-down products and clotting parameters.
    Gormsen J; Laursen B
    Thromb Diath Haemorrh; 1967 May; 17(3-4):467-81. PubMed ID: 4231951
    [No Abstract]   [Full Text] [Related]  

  • 46. Assay of the antifibrinolytic activity in human plasma by means of the lysis time method.
    Ygge J; Berg W; Korsan-Bengtsen K
    Thromb Diath Haemorrh; 1968 Dec; 20(3):561-73. PubMed ID: 4237141
    [No Abstract]   [Full Text] [Related]  

  • 47. Plasminogen assay by means of the lysis time method.
    Berg W; Korsan-Bengtsen K; Ygge J
    Thromb Diath Haemorrh; 1965 Sep; 14(1-2):127-44. PubMed ID: 16955971
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Microcalorimetric study of a heparin complex formation with thrombogenic proteins].
    Rozenfel'd MA; Piruzian LA; Khavkina LS; Petrosian MT
    Izv Akad Nauk SSSR Biol; 1972; 3():446-50. PubMed ID: 4666466
    [No Abstract]   [Full Text] [Related]  

  • 49. Change of viscoelastic property and morphology of fibrin affected by antithrombin III and heparin: QCM-Z and AFM study.
    Jung H; Tae G; Kim YH; Johannsmann D
    Colloids Surf B Biointerfaces; 2009 Jan; 68(1):111-9. PubMed ID: 19004623
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Heparin complex formation with plasma fibrin-stabilizing factor in vitro].
    Ul'ianov AM; Kudriashov BA; Liapina LA
    Biokhimiia; 1973; 38(6):1281-7. PubMed ID: 4802010
    [No Abstract]   [Full Text] [Related]  

  • 51. [Change in fibrinogen and enzymatic and nonenzymatic fibrinolytic activity of blood in patients with low-degree rheumatic heart disease under the effect of treatment with acetylsalicylic acid].
    Andreenko GV; Samsonov MA; Paramonova EG; Karabasova MA; Redziuk LA
    Ter Arkh; 1976; 48(11):64-70. PubMed ID: 139704
    [No Abstract]   [Full Text] [Related]  

  • 52. A serum-induced defect in fibrin formation.
    Deykin D; Silversmith P; Ashford T
    J Lab Clin Med; 1970 Nov; 76(5):761-74. PubMed ID: 4249037
    [No Abstract]   [Full Text] [Related]  

  • 53. Extended monitoring of hemostatic activation after varicose vein surgery under general anesthesia.
    Hinterhuber G; Böhler K; Kittler H; Quehenberger P
    Dermatol Surg; 2006 May; 32(5):632-9. PubMed ID: 16706757
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The phylogeny of baboon fibrin-fibrinolysin.
    Hampton JW; McKee P
    Acta Zool Pathol Antverp; 1969 May; 48():59-62. PubMed ID: 4271524
    [No Abstract]   [Full Text] [Related]  

  • 55. Properties of a heparin-poly(vinyl alcohol) hydrogel coating.
    Goosen MF; Sefton MV
    J Biomed Mater Res; 1983 Mar; 17(2):359-73. PubMed ID: 6841373
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Mechanism of inhibition of non-enzymatic fibrinolysis by a spleen factor].
    Liapina LA; Azieva LD
    Biokhimiia; 1985 Jan; 50(1):69-73. PubMed ID: 3978152
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples.
    Lewis MR; Callas PW; Jenny NS; Tracy RP
    Thromb Haemost; 2001 Dec; 86(6):1495-500. PubMed ID: 11776319
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The cleavage sequence of fibrinopeptide A from fibrinogen fragment E by thrombin, atroxin or batroxobin.
    Meh DA; Siebenlist KR; Bergtrom G; Mosesson MW
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):107-12. PubMed ID: 8457636
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The quantitation of fibrinogen or fibrin split products. Some critical remarks.
    Merskey C
    Thromb Diath Haemorrh Suppl; 1969; 36():195. PubMed ID: 4246463
    [No Abstract]   [Full Text] [Related]  

  • 60. [The fibrin and plasma-protein content of human thrombi].
    Jakab T; Haeberli A; Straub PW
    Schweiz Med Wochenschr; 1979 Sep; 109(37):1389. PubMed ID: 482912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.